Chronic Airways Assessment Test (CAAT)
Chronic Airways Assessment Test: A unified tool for assessing chronic airway diseases
CAAT can now be used for assessing respiratory health status in people with asthma, not just COPD
A simple and standardized health status measure
A standardized, easy to administer, health status measure for use across obstructive lung diseases.
Structure and components of the CAAT
8-items assessing aspects of disease relevant to patients.
Development and validation
The COPD assessment test (CAT) and the Chronic Airways Test (CAAT) were developed by an interdisciplinary group of international experts with support from GSK.
CAT and CAAT activities are monitored by a supervisory council that includes independent experts, one of which is chair of the council.
CAT, COPD Assessment Test, CAAT, Chronic Airways Assessment Test and the CAT logo are trademarks of the GSK group of companies.
Implementation and resources
Scan the QR code for the CAAT User Guide.
Documents for download
Read more details at
Fecha de publicación
September 2025
Categorías asociadas al artículo
Noticias relacionadas
Climate change and respiratory health: implications for respiratory clinicians in primary and specialist care
Review on climate change and respiratory health, focusing on chronic respiratory diseases and implications for primary and specialist care.
cfDNA profiling in COPD
Whole-genome cfDNA profiling identifies molecular clusters and pathways associated with oxidative damage and airflow limitation in COPD patients.
Video del evento: Transformando la EPOC, claves para un manejo proactivo
Conferencia sobre el manejo proactivo de la EPOC centrada en el infradiagnóstico, el control clínico y el seguimiento estructurado del paciente.
Exploring the association between eosinophils and autoimmunity in COPD
Study exploring the association between eosinophils and circulating autoantibodies in COPD patients, considering airflow limitation and smoking status.
ECLIPSE: un estudio de tres años que cambió nuestra forma de entender la EPOC
A 20 años de ECLIPSE, repasamos el estudio que transformó la comprensión de la EPOC, revelando su heterogeneidad, progresión y biomarcadores clave.
Lessons from the ANTES B+ study
Lessons from the ANTES B+ study highlighting challenges in COPD clinical trials, recruitment difficulties, and implications for future study design.
Imagen obtenida de la presentación